The net operating income (EBIT) in H1 FY23 was CHF 280 million, compared to CHF 324 million during the same period the previous year, the company said in a press release.
Despite these setbacks, due to its robust positioning in the specialty segment and decisive actions, EMS succeeded in maintaining an EBITDA margin of 25.9 per cent, though lower than the previous year's 27.5 per cent.
The company’s H1 FY23 EBIT margin reached 23.7 per cent, compared to 25.2 per cent the previous year. The operating cash flow (EBITDA) came to CHF 306 million, a drop from the previous year's figure of CHF 354 million.
EMS forecasts net sales and net operating income (EBIT) for the entirety of 2023 to fall below the previous year's levels.
ALCHEMPro News Desk (DP)
Receive daily prices and market insights straight to your inbox. Subscribe to AlchemPro Weekly!
marketing@alchempro.com
